Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.49 |
| ▸ | BTK | Q06187 | 14/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591069 | 0.76 | JAK3 (0.48) | JAK3BTKPTK2FLT4 | |
| SCHEMBL1662570 | 0.74 | LRRK2 (0.42) | HTR2AHTR2CPLK4 | |
| SCHEMBL1663056 | 0.72 | JAK3 (0.49) | JAK3PTK2FLT4 | |
| SCHEMBL1662711 | 0.72 | JAK3 (0.42) | JAK3BTKPTK2PLK4 | |
| SCHEMBL1663991 | 0.71 | JAK3 (0.39) | JAK3BTK | |
| SCHEMBL1662522 | 0.71 | PTK6 (0.42) | JAK3HTR2AHTR2CFLT4PLK4 | |
| SCHEMBL1665097 | 0.71 | JAK3 (0.50) | JAK3BTK | |
| SCHEMBL1662898 | 0.71 | JAK3 (0.39) | JAK3BTKHTR2AHTR2CFLT4 | |
| SCHEMBL1662830 | 0.69 | JAK3 (0.41) | JAK3BTKHTR2CFLT4PLK4 | |
| SCHEMBL1662793 | 0.68 | PLK4 (0.46) | JAK3BTKPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |